

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA 49160 Insp GMP/GDP/IMP 49160/26807038-0008[H]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :
Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : ERAMOL (UK) LTD

Site address : ERAMOL (UK) LTD, UNIT 9, NORTH DOWNS BUSINESS PARK, LIMEPIT LANE, DUNTON GREEN, SEVENOAKS, TN13 2TL, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA 49160 in accordance with Regulation 17 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 23/01/2024 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

-
- (1) *Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.*
 - (2) *These requirements fulfil the GMP recommendations of WHO.*

Part 2

Human Medicinal Products

1. MANUFACTURING OPERATIONS

[1.1] Sterile Products

[1.1.3] Batch certification

[1.2] Non-sterile products

[1.2.1] Non-Sterile Products (processing operations for the following dosage forms)

[1.2.1.1] Capsules, hard shell

[1.2.1.5] Liquids for external use

[1.2.1.6] Liquids for internal use

[1.2.1.13] Tablets

[1.2.2] Batch certification

[1.3] Biological medicinal products

[1.3.2] Batch certification

[1.3.2.5] Biotechnology products

[1.5] Packaging

[1.5.1] Primary packaging

[1.5.1.1] Capsules, hard shell

[1.5.1.2] Capsules, soft shell

[1.5.1.5] Liquids for external use

[1.5.1.6] Liquids for internal use

[1.5.1.13] Tablets

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.3] Chemical/Physical

2. IMPORTATION OF MEDICINAL PRODUCTS

[2.1] Quality control testing of imported medicinal products

[2.1.3] Chemical/Physical

[2.2] Batch certification of imported medicinal products

[2.2.1] Sterile Products

[2.2.1.1] Aseptically prepared

[2.2.1.2] Terminally sterilised

[2.2.2] Non-sterile products

[2.2.3] Biological medicinal products

[2.2.3.5] Biotechnology products

[2.3] Other Importation Activities

[2.3.1] Site of Physical Importation

[2.3.2] Importation of Intermediate which undergoes further processing

29/04/2024 Name and signature of the authorised person of the Competent Authority of United Kingdom
Confidential
Medicines and Healthcare products Regulatory Agency
Tel : Confidential

MHRA-GMDP

MHRA

MHRA-GMDP

MHRA